News

ORIC Pharmaceuticals Presents Evidence of Glucocorticoid Receptor-Medicated Cancer Treatment Resistance at the AACR Annual Meeting
April 2, 2019

ORIC Pharmaceuticals Appoints Edna Chow Maneval, PhD, as Senior Vice President of Clinical Development
March 4, 2019

ORIC Pharmaceuticals to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
February 20, 2019

ORIC Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 2, 2019

ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business Officer 
November 26, 2018

ORIC Pharmaceuticals to Present at Upcoming Investor Conference
November 19, 2018

ORIC to Participate at BTIG Biotech Conference
October 22, 2018

ORIC Pharmaceuticals announces Pratik Multani, MD, as Chief Medical Officer
September 17, 2018

ORIC to Participate at Citi 13th Annual Biotech Investor Conference
August 30, 2018

ORIC has appointed Jacob Chacko, MD as Chief Executive Officer
May 7, 2018

ORIC Pharmaceuticals Announces $50 Million Series C Financing to Support Novel Therapies for Treatment-Resistant Cancers
February 21, 2018

ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for Oncology
October 27, 2017

ORIC Pharmaceuticals Announces $53 Million Series B Financing to Support Discovery and Development of Novel Therapies for Treatment-Resistant Cancers
December 2, 2015

ORIC pharmaceuticals appoints Valeria Fantin, Ph.D. as Chief Scientific Officer
August 17, 2015

ORIC pharmaceuticals adds Richard Scheller, Ph.D., former CSO of Genentech, to its Board of Directors
March 9, 2015

ORIC pharmaceuticals adds Richard Heyman, Ph.D., former CEO of Aragon and Seragon, to its Board of Directors
March 9, 2015